Erratum: Reduced IFNI 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes(Nature Communications (2014) 5 (5699) 10.1038/ncomms6699);Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes

Nature Communications

Volumn 5, Issue , 2014, Pages

  Terczyńska Dyla, Ewa ^a   Bibert, Stephanie ^b   Duong, Francois H T ^c,d   Krol, Ilona ^c,d   Jørgensen, Sanne ^a   Collinet, Emilie ^b   Kutalik, Zoltán ^e,f   Aubert, Vincent ^b   Cerny, Andreas ^g   Kaiser, Laurent ^h   Malinverni, Raffaele ⁱ   Mangia, Alessandra ^j   Moradpour, Darius ^b   Müllhaupt, Beat ^k   Negro, Francesco ^l   Santoro, Rosanna ^j   Semela, David ^m   Semmo, Nasser ⁿ   Heim, Markus H ^c,d   Bochud, Pierre Yves ^b   Hartmann, Rune ^a   Rubbia Brandt, Laura ^o   Martinetti, Gladys ^p   Gorgievski, Meri ^q   Dufour, Jean François ^r   Hirsch, Hans ^c   Helbling, Beat ^s,t   Regenass, Stephan ^k   Dollenmaier, Guenter ^u   Cathomas, Gieri ^v   more..

^a AARHUS UNIVERSITY   (Denmark)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^g Epatocentro Ticino   (Switzerland)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ Division of Infectious Diseases Pourtalès Hospital   (Switzerland)

^j CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l UNIVERSITY HOSPITAL   (Switzerland)

^m CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁿ UNIVERSITY OF BERN   (Switzerland)

^o Hôpital Cantonal   (Switzerland)

^p EOLAB   (Switzerland)

^q Fachbereich Virologie Molekularbiologie   (Switzerland)

^r UNIVERSITY OF BERN   (Switzerland)

^s Stadtspital Waid   (Switzerland)

^t Gemeinschaftspraxis Gastroenterologie Bethanien   (Switzerland)

^u Institut für Klinische Mikrobiologie und Immunologie   (Switzerland)

^v Laboratory for Pathology of Infectious Diseases   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON LAMBDA 4; MESSENGER RNA; PEGINTERFERON ALPHA; PROLINE; RIBAVIRIN; SERINE; UNCLASSIFIED DRUG;

CANCER; DISEASE TREATMENT; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC VARIATION; PROTEIN; VIRUS;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS C; GENE; GENE REPRESSION; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENETICS; INTERFERON STIMULATED GENE; MAJOR CLINICAL STUDY; NONHUMAN; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS IMMUNITY;

HEPATITIS C VIRUS;

EID: 84936848014     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8280     Document Type: Erratum

References (34)

1. Shepard, C. W., Finelli, L. & Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558-567 (2005).
2. Heim, M. H. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat. Rev. Immunol. 13, 535-542 (2013).
3. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
4. Rauch, A. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338-1345 (2010).
5. Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009).
6. Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009).
7. Asselah, T. et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57, 516-524 (2008).
8. Chen, L. et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128, 1437-1444 (2005).
9. Sarasin-Filipowicz, M. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. USA 105, 7034-7039 (2008).
10. Dill, M. T. et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140, 1021-1031 (2011).
11. Honda, M. et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139, 499-509 (2010).
12. Urban, T. J. et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52, 1888-1896 (2010).
13. Aka, P. V. et al. Association of the IFNL4-DeltaG allele with impaired spontaneous clearance of hepatitis C virus. J. Infect. Dis. 209, 350-354 (2014).
14. Thomas, D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801 (2009).
15. Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164-171 (2013).
16. Bibert, S. et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J. Exp. Med. 210, 1109-1116 (2013).
17. Hamming, O. J. et al. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 32, 3055-3065 (2013).
18. Smith, K. R. et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med. 3, 57 (2011).
19. Gad, H. H. et al. Interferon-lambda is functionally an interferon but structurally related to the IL-10 family. J. Biol. Chem. 284, 20869-20875 (2009).
20. Miknis, Z. J. et al. Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferon-lambdaR1. J. Mol. Biol. 404, 650-664 (2010).
21. Santantonio, T., Wiegand, J. & Gerlach, J. T. Acute hepatitis C: current status and remaining challenges. J. Hepatol. 49, 625-633 (2008).
22. Francois-Newton, V. et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS ONE 6, e22200 (2011).
23. Sarasin-Filipowicz, M. et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol. Cell. Biol. 29, 4841-4851 (2009).
24. Jouvin-Marche, E. et al. Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels. J. Infect. Dis. 209, 1907-1915 (2014).
25. Galmozzi, E. & Aghemo, A. Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 DeltaG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. J. Clin. Virol. 59, 274-275 (2014).
26. Ahlenstiel, G., Booth, D. R. & George, J. Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Antivir. Ther. 17, 1163-1170 (2012).
27. Holmes, J. A., Desmond, P. V. & Thompson, A. J. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J. Viral Hepat. 19, 677-684 (2012).
28. Muir, As. J. IL28B in the era of direct-acting antivirals for hepatitis C. J. Clin. Gastroenterol. 47, 222-227 (2013).
29. Zeuzem, S. et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. New Engl. J. Med. 369, 630-639 (2013).
30. Meissner, E. G. et al. IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J. Infect. Dis. 209, 1700-1704 (2014).
31. Bibert, S. et al. The IFNL3/4 [DELTA]G variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS 28, 1885-1889 (2014).
32. Dellgren, C., Gad, H. H., Hamming, O. J., Melchjorsen, J. & Hartmann, R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun. 10, 125-131 (2009).
33. Jorns, C. et al. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha. J. Med. Virol. 78, 74-82 (2006).
34. Prasad, L. et al. Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int. J. Epidemiol. 36, 731-737 (2007).